Nicotine Addiction Therapeutics Drugs and Vaccine Pipeline 2017 provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.
Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies analysed in report are Addex Therapeutics Ltd, C4X Discovery Holdings PLC, Chronos Therapeutics Ltd, CV Sciences Inc, Hager Biosciences LLC, Heptares Therapeutics Ltd, Omeros Corp.
Get this 63 pages report at www.reportsnreports.com/contacts/d…aspx?name=1157458.
Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 11 and 2 respectively.
Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Nicotine Addiction Drugs and Vaccine candidate in pipeline are (cannabidiol + nicotine bitartrate), 18-MC, ADX-71441, AT-1001, CTDP-002, EORA-101, Monoclonal Antibodies for Nicotine Addiction, Noribogaine, OMS-405, OMS-527, Small Molecule for Nicotine Addiction, Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders, Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders, Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction, Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction, Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders, Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders, Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders, URB-694, Vaccine for Nicotine Addiction, Vaccine for Nicotine Addiction, Vaccine for Nicotine Addiction.
Access this report at www.reportsnreports.com/purchase.aspx?name=1157458
The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
Report helps to procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies and recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. You can find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System) and also Classify potential new clients or partners in the target demographic.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Key Topics Covered:
- Global Markets Direct Report Coverage
- Nicotine Addiction - Overview
- Nicotine Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Nicotine Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nicotine Addiction - Companies Involved in Therapeutics Development